Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Slow-wave Sleep Enhancement in Those at Risk for Alzheimer's Disease: Links With Memory, Excitotoxicity, and Plasma A-beta
Authors not listed
University of Pittsburgh · 2022
Abstract
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years. Behavioral interventions have shown promise for mitigating neurodegeneration and cognitive impairments. Sleep is a modifiable health behavior that is critical for cognition and deteriorates with advancing age and Alzheimer's disease. Thus, it is a priority to examine whether improving sleep modifies Alzheimer's disease pathophysiology and cognitive function. Extant research suggests that deeper, more consolidated sleep is positively associated with memory and executive functions and networks that underlie these processes. Preliminary studies confirm that time-in-bed restriction interventions increase sleep efficiency and non-rapid eye movement slow-wave activity (SWA) and suggest that increases in SWA are associated with improved cognitive function. SWA reflects synaptic downscaling predominantly among prefrontal connections. Downscaling of prefrontal connections with the hippocampus during sleep may help to preserve the long-range connections that support memory and cognitive function. In pre-clinical Alzheimer's disease, hyperactivation of the hippocampus is thought to be excitotoxic and is shown to leave neurons vulnerable to further amyloid deposition. Synaptic downscaling through SWA may mitigate the progression of Alzheimer's disease through these pathways. The proposed study will behaviorally increase sleep depth (SWA) through four weeks of time-in-bed restriction in older adults characterized on amyloid deposition and multiple factors associated with Alzheimer's disease risk. This study will examine whether behaviorally enhanced SWA reduces hippocampal hyperactivation, leading to improved task-related prefrontal-hippocampal connectivity, plasma amyloid levels, and cognitive function. This research addresses whether a simple, feasible, and scalable behavioral sleep intervention improves functional neuroimaging indices of excitotoxicity, Alzheimer's pathophysiology, and cognitive performance.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2022). Slow-wave Sleep Enhancement in Those at Risk for Alzheimer's Disease: Links With Memory, Excitotoxicity, and Plasma A-beta. <em>University of Pittsburgh</em>. https://clinicaltrials.gov/study/NCT05138848
Vancouver
Anonymous. Slow-wave Sleep Enhancement in Those at Risk for Alzheimer's Disease: Links With Memory, Excitotoxicity, and Plasma A-beta. University of Pittsburgh. 2022.
BibTeX
@misc{anon2022Slowwa,
title = {Slow-wave Sleep Enhancement in Those at Risk for Alzheimer's Disease: Links With Memory, Excitotoxicity, and Plasma A-beta},
author = {Anonymous},
journal = {University of Pittsburgh},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biological Psychiatry 1996
Preprint · OA
Circadian rest—activity rhythm disturbances in alzheimer's disease
Antioxidants 2021
Open access · CC-BY
Sirtuins and Renal Oxidative Stress
Nature 2014
Preprint · OA
REST and stress resistance in ageing and Alzheimer’s disease
Eli Lilly and Company 2014
Open access · US-GOV
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Pirogov Russian National Research Medical University 2023
Open access · US-GOV
RUSS-AGE, CREATING OF A BIOLOGICAL AGE CALCULATOR AND STUDY OF AGING PHENOTYPES IN THE RUSSIAN POPULATION
Nature Communications 2019
Open access · CC-BY